Search results for "Cell transplantation"

showing 10 items of 493 documents

When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

2017

When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

AdultMaleAdolescentCongenital cytomegalovirus infectionCytomegalovirusHematologic Neoplasms03 medical and health sciences0302 clinical medicinemedicineHumansProspective StudiesProgenitor cellProspective cohort studyAgedTransplantationbusiness.industryAntiviral therapyHematologyMiddle Agedmedicine.diseaseAllograftsTransplantationGraft-versus-host disease030220 oncology & carcinogenesisHematologic NeoplasmsImmunologyCytomegalovirus InfectionsFemaleStem cellbusiness030215 immunologyStem Cell TransplantationBone marrow transplantation
researchProduct

An Assessment of the Effect of Human Herpesvirus-6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation

2010

Human herpesvirus-6 (HHV-6) may enhance cytomegalovirus (CMV) replication in allogeneic stem cell transplant (allo-SCT) recipients either through direct or indirect mechanisms. Definitive evidence supporting this hypothesis are lacking. We investigated the effect of HHV-6 replication on active CMV infection in 68 allo-SCT recipients. Analysis of plasma HHV-6 and CMV DNAemia was performed by real-time PCR. Enumeration of pp65 and IE-1 CMV-specific IFNgamma CD8(+) and CD4(+)T cells was performed by intracellular cytokine staining. HHV-6 DNAemia occurred in 39.8% of patients, and was significantly associated with subsequent CMV DNAemia in univariate (P=.01), but not in multivariate analysis (P…

AdultMaleAdolescentInteractionHerpesvirus 6 Humanmedicine.medical_treatmentvirusesCongenital cytomegalovirus infectionRoseolovirus InfectionsVirus ReplicationYoung AdultHomologous chromosomemedicineHumansTransplantation HomologousCMV replicationAgedImmunosuppression TherapyTransplantationHuman herpesvirus 6 (HHV-6)biologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesImmunosuppressionHematologyMiddle Agedmedicine.diseasebiology.organism_classificationAllo-SCT recipientVirologyCMV immune responseTransplantationViral replicationCytomegalovirus InfectionsDNA ViralImmunologyFemaleVirus ActivationHuman herpesvirus 6Stem cellCytomegalovirus (CMV)businessCD8Biology of Blood and Marrow Transplantation
researchProduct

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR ass…

2013

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center

AdultMaleAdolescentPcr assayCongenital cytomegalovirus infectionCytomegalovirusReal-Time Polymerase Chain ReactionSingle CenterHumansMedicineDna viralAgedMonitoring PhysiologicRetrospective StudiesTransplantationbusiness.industryAntiviral therapyvirus diseasesHematologyCmv dnaemiaAllo sctMiddle AgedAllograftsmedicine.diseaseVirologyReal-time polymerase chain reactionHematologic NeoplasmsCytomegalovirus InfectionsDNA ViralImmunologyFemalebusinessStem Cell TransplantationBone Marrow Transplantation
researchProduct

Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results…

2015

Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.Peripheral circulating CD34+ stem cells, colony-forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF-GEMM), colony-forming unitgranulocyte/macrophage (CFU-GM), and erythroidburst-forming units (BFU-E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy con…

AdultMaleAdolescentbeta-ThalassemiaHematopoietic Stem Cell TransplantationPilot ProjectsMiddle AgedHematopoietic Stem CellsPrognosisSettore MED/15 - Malattie Del SangueYoung AdultPeripheral CD34+ stem cells beta-thalassemiaTreatment OutcomeCase-Control StudiesHumansFemaleBiomarkersAgedFollow-Up Studies
researchProduct

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

2016

We investigated a possible interaction between age-associated risk and HLA-mismatch associated risk on prognosis in different age categories of recipients of unrelated hematopoietic stem cell transplants (HSCT) (n=3019). Patients over 55 years of age transplanted with 8/10 donors showed a mortality risk of 2.27 (CI 1.70–3.03, P<0.001) and 3.48 (CI 2.49–4.86, P<0.001) when compared to 10/10 matched patients in the same age group and to 10/10 matched patients aged 18–35 years, respectively. Compared to 10/10 matched transplantations within each age category, the Hazards Ratio for 8/10 matched transplantation was 1.14, 1.40 and 2.27 in patients aged 18–35 years, 36–55 and above 55 years. Model…

AdultMaleAdolescentmedicine.medical_treatmentAge categoriesHematopoietic stem cell transplantationHuman leukocyte antigenHistocompatibility TestingKaplan-Meier Estimate03 medical and health sciencesYoung Adult0302 clinical medicineHLA AntigensRisk FactorsCell Therapy & ImmunotherapymedicineHumansPublic Health SurveillanceYoung adultMortalityAgedbusiness.industryHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationHematopoietic stem cellHematologyArticlesMiddle Aged3. Good healthHistocompatibilitysurgical procedures operativemedicine.anatomical_structure030220 oncology & carcinogenesisHistocompatibilityImmunologyFemalebusinessUnrelated Donors030215 immunologyHaematologica
researchProduct

Bone marrow after autologous blood stem cell transplantation and total body irradiation: magnetic resonance and chemical shift imaging.

1993

Magnetic resonance studies of the lumbar, pelvic, and femoral bone marrow were performed in 10 patients after autologous blood stem cell transplantation, including total body irradiation and myeloablative chemotherapy. The posttreatment interval varied between 2 and 6 yr. The appearance on T1-weighted images and the quantitative data obtained from chemical shift imaging (relative fat signal) were compared to 10 age-matched healthy volunteers. The classification of the T1-weighted images yielded no significant differences between the two groups. Chemical shift imaging by determination of the relative fat signal was able to detect a significant fatty replacement of the patients' lumbar (p < .…

AdultMaleAdolescentmedicine.medical_treatmentBiomedical EngineeringBiophysicsBlood cellLumbarBone MarrowmedicineHumansRadiology Nuclear Medicine and imagingFemurChildPelvic BonesChemotherapyLeukemiaLumbar Vertebraemedicine.diagnostic_testChemistrybusiness.industryHematopoietic Stem Cell TransplantationMagnetic resonance imagingTotal body irradiationMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingTransplantationmedicine.anatomical_structureAcute DiseaseFemaleBone marrowStem cellNuclear medicinebusinessWhole-Body IrradiationMagnetic resonance imaging
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT).

2010

Aims: To establish whether or not the state of patient oral health can influence the occurrence and/or severity of oral mucositis during hematopoietic progenitor cell transplantation (HPCT). Materials and Methods: The study included 72 patients awaiting HPCT. Prior to transplantation, clinical exploration and radiology were carried out and oral photographs were taken. This evaluated the extent of caries present, the number of missing teeth and the number of dental fillings in each patient; CAO (Caries and Obturations Index) DMFS (Decayed, Missing, and Filled Surfaces) and Restoration Indices were calculated. Gingival pathology was also examined by means of the Ainamo and Bay Gingival Bleedi…

AdultMaleAdolescentmedicine.medical_treatmentDentistryOral HealthHematopoietic stem cell transplantationOral healthOral hygieneSeverity of Illness IndexYoung AdultSeverity of illnessmedicineMucositisHumansYoung adultChildGeneral DentistryStomatitisAgedStomatitisbusiness.industryHematopoietic Stem Cell TransplantationMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Transplantationstomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsbusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules.

2009

Purpose. The aim of the study was to analyze patients’ busulfan (BU) exposure after oral administration of extemporeanously prepared BU capsules prior to blood stem cell transplantation. Methods. Patients were treated with 1 mg/kg body weight BU administered orally every 6h on each of 4 consecutive days prior to blood stem cell transplantation. Each BU dose was administered in 1 gelatine capsule to be swallowed and containing the individually calculated dose of pure BU active substance. Blood samples were obtained from 6 adult patients 0, 30, 60, 90, 120, 180, 240, 300, and 360 min after the 1st, 5th, and 13th BU dose, frozen and analyzed subsequently by using a HPLC assay with UV detectio…

AdultMaleAlkylating AgentsTransplantation ConditioningDrug CompoundingAdministration OralCapsulesPharmacologyHplc assayPharmacokineticsOral administrationMedicineHumansPharmacology (medical)BusulfanCyclophosphamideChromatography High Pressure LiquidPeripheral Blood Stem Cell Transplantationmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryCapsuleMiddle AgedTransplantationOncologyTherapeutic drug monitoringConcomitantArea Under CurveDrug Therapy CombinationFemaleSpectrophotometry UltravioletDrug MonitoringbusinessBusulfanmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acut…

2013

Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was man…

AdultMaleCancer ResearchAdolescentPhases of clinical researchGene ExpressionPharmacologyNucleoside transporterEquilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 1Young AdultBone MarrowAntineoplastic Combined Chemotherapy ProtocolsmedicineIdarubicinHumansAgedPredictive markerbiologyElacytarabinebusiness.industryCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyInduction ChemotherapyMiddle AgedLeukemia Myeloid AcuteTreatment OutcomeOncologybiology.proteinCytarabineFemalebusinessIdarubicinmedicine.drugLeukemialymphoma
researchProduct